<?xml version="1.0" encoding="UTF-8"?>
<p>The reasons why such medical needs remain unmet are complex but include comparatively low R&amp;D investment [
 <xref rid="B11-tropicalmed-04-00053" ref-type="bibr">11</xref>]—particularly for translational research [
 <xref rid="B12-tropicalmed-04-00053" ref-type="bibr">12</xref>]—and research intensity [
 <xref rid="B13-tropicalmed-04-00053" ref-type="bibr">13</xref>] for certain tropical diseases. Limited commercial incentives—particularly compared to products for diseases prevalent in high-income countries—have hindered many multinational pharmaceutical companies from bringing their immense product development expertise and resources to bear in the area of tropical diseases [
 <xref rid="B12-tropicalmed-04-00053" ref-type="bibr">12</xref>,
 <xref rid="B14-tropicalmed-04-00053" ref-type="bibr">14</xref>,
 <xref rid="B15-tropicalmed-04-00053" ref-type="bibr">15</xref>]. 
</p>
